(Bloomberg) -- A formerly cautious analyst at SVB Leerink has changed his tune on the potential sales of Gilead Sciences Inc.’s Covid-19 treatment, remdesivir.Even bullish Wall Street analysts have been critical of Gilead’s chances of making a profit from the treatment, which received an emergency use designation from U.S. regulators in May. Public advocates have argued against drug and vaccine makers making any profit from the global pandemic but SVB Leerink analyst Geoffrey Porges is now forecasting that sales of remdesivir may reach $7.7 billion in 2022.Less than two months ago, Porges had said investors were giving a “generous amount of credit” for a drug that likely won’t be sold for a profit.The latest change is reason enough for Porges to raise his rating on Gilead shares to outperform from market perform, and increase his price target to $94, just $3 shy of the current Street high target. The new target,...
President Donald Trump's administration plans to bar Chinese passenger carriers from flying to the United States starting in mid-June as it pressures Beijing to allow U.S. air carriers to resume flights, three U.S. and airline officials briefed on the matter told Reuters. The move, set to be announced on Wednesday, penalizes China after Beijing failed to comply with an existing agreement on flights between the world's two largest economies. The restrictions are expected to take effect on June 16 but the date could be moved up by Trump, the people briefed on the matter said, speaking on condition of anonymity....
The coronavirus pandemic and accompanying financial crisis is putting particular pressure on the finances of student loan borrowers and on Congress to do something about a “broken” system....